Lipid-Lowering Agents - Mauritius

Mauritius

The Lipid-Lowering Agents market in Mauritius is projected to reach a revenue of US$0.57m in 2024.
It is expected to show an annual growth rate of 1.03% from 2024 to 2029, resulting in a market volume of US$0.60m by 2029.
In global comparison, United States is anticipated to generate the highest revenue with US$4,461.00m in 2024.
In Mauritius, there is a growing demand for lipid-lowering agents due to an increasing prevalence of cardiovascular diseases in the population.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Mauritius has been on the rise in recent years.

Customer preferences: The increasing prevalence of cardiovascular diseases and rising awareness about the importance of maintaining healthy cholesterol levels have been the primary drivers of the demand for Lipid-Lowering Agents in Mauritius. Additionally, the growing geriatric population and sedentary lifestyles have also contributed to the increasing demand for these drugs.

Trends in the market: The market for Lipid-Lowering Agents in Mauritius has witnessed a trend towards the use of combination therapies, which offer better efficacy and convenience to patients. The trend is likely to continue as more combination therapies become available in the market. Furthermore, the market is also witnessing a shift towards the use of generic drugs, which are more affordable and accessible to a larger population.

Local special circumstances: Mauritius has a high prevalence of non-communicable diseases, including cardiovascular diseases, which has led to a high demand for Lipid-Lowering Agents. Additionally, the government of Mauritius has been actively promoting healthy lifestyles and preventive healthcare, which has created awareness about the importance of maintaining healthy cholesterol levels.

Underlying macroeconomic factors: The pharmaceutical industry in Mauritius is heavily regulated, which has led to a limited number of players in the market. However, the government has been taking steps to promote investment in the pharmaceutical sector, which is likely to lead to increased competition and innovation in the market. Furthermore, the growing healthcare sector in Mauritius, coupled with the increasing demand for Lipid-Lowering Agents, is likely to create opportunities for growth in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.